An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome p4502c9 in vivo activity

Drug Metabolism and Disposition

Volumn 42, Issue 3, 2014, Pages 323-325

  Cherala, Ganesh ^a   Pearson, Jacob ^b   Maslen, Cheryl ^c   Edelman, Alison ^d  

^a OREGON STATE UNIVERSITY   (United States)

^b Molecular and Medical Genetics   (United States)

^c Departments of Obstetrics and Gynecology   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; SUBSTRATE SPECIFICITY; TOLBUTAMIDE; YOUNG ADULT;

EID: 84893856196     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054346     Document Type: Article

References (19)

1. Battaile KP, Battaile BC, Merkens LS, Maslen CL, and Steiner RD (2001) Carrier frequency of the common mutation IVS8-1G.C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome. Mol Genet Metab 72:67-71.
2. Chang SY, Chen C, Yang Z, and Rodrigues AD (2009) Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos 37:1667-1675.
3. Dinger J, Minh TD, Buttmann N, and Bardenheuer K (2011) Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 117:33-40.
4. Edelman A, Munar M, Elman MR, Koop D, and Cherala G (2012) Effect of the ethinylestradiol/ levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. Br J Clin Pharmacol 74:510-514.
5. Edelman AB, Cherala G, Munar MY, Dubois B, McInnis M, Stanczyk FZ, and Jensen JT (2013) Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception 87:220-226.
6. Ellison J, Thomson AJ, Greer IA, and Walker ID (2000) Drug Points: Apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ 321:1382. Accessed on 8/16/2013.
7. European Medicines Agency (2010). Guideline on the investigation of bioequivalence [cited DATE]. Available from: http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf. Accessed on 8/16/2013.
8. Gainer E (2003) In vitro studies, post-marketing data do not corroborate levonorgestrel-warfarin interaction [cited DATE]. Available from: http://www.bmj.com/content/321/7273/1382?tab=responses.
9. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
10. Hill CE, Duncan A, Wirth D, and Nolte FS (2006) Detection and identification of cytochrome P-450 2C9 alleles *1, *2, and *3 by high-resolution melting curve analysis of PCR amplicons. Am J Clin Pathol 125:584-591.
11. Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, Walchner-Bonjean M, Hering U, Jakob V, and Rodamer M, et al. (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165-171.
12. Laine K, Yasar U, Widén J, and Tybring G (2003) A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol 93:77-81.
13. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
14. Sandberg M, Johansson I, Christensen M, Rane A, and Eliasson E (2004) The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32: 484-489.
15. Seaman HE, de Vries CS, and Farmer RD (2003) Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod 18:515-521.
16. Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, and Gaedigk A, et al. (2005) Effect of a triphasic oral contraceptive on drugmetabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 45:1413-1421.
17. Trussell J (2007) The cost of unintended pregnancy in the United States. Contraception 75: 168-170.
18. US Food and Drug Administration (2003) Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, US Food and Drug Administration, Bethesda, MD.
19. Yasar U, Dahl ML, Christensen M, and Eliasson E (2002) Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 54: 183-185.